1 San Juan de Dios Hospital, Santiago, Chile.
2 Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department de Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619834342. doi: 10.1177/1076029619834342.
Warfarin and acenocoumarol are used in various cardiovascular disorders to improve the prognosis of patients with thromboembolic disease. However, there is a lack of substantial efficacy and safety data on antithrombotic prophylaxis in several countries, particularly in Latin America. The aim of this study was to provide information about the efficacy of anticoagulants in Chilean patients. Data were collected from databases of the Western Metropolitan Health Service, Santiago, Chile. We identified 6280 records of patients receiving anticoagulant treatment. The three most common diagnoses were rhythm disorder (43.7%), venous thrombosis (22%), and valvular prosthesis (10.7%). The majority of patients (98.5%) received acenocoumarol while 1.5% of patients received warfarin, at weekly therapeutic doses of 13.6 mg and 30.4 mg, respectively. For total diagnoses, the median time in the therapeutic range was 50%. However, better results, 66.7%, were observed when a telemedicine strategy was used only in Santiago Province. Our findings emphasize that in Chile, where the number of patients receiving anticoagulant treatment increases every year, telemedicine, by committed teams, improves the use of oral anticoagulants and is able to increase quality indicators of anticoagulant treatment care.
华法林和醋硝香豆素用于各种心血管疾病，以改善血栓栓塞性疾病患者的预后。然而，在一些国家，特别是拉丁美洲国家，缺乏关于抗血栓预防的大量疗效和安全性数据。本研究旨在提供有关智利患者抗凝剂疗效的信息。数据来自智利圣地亚哥西部大都市卫生服务数据库。我们确定了 6280 例接受抗凝治疗的患者记录。最常见的三种诊断是节律障碍（43.7%）、静脉血栓形成（22%）和瓣膜假体（10.7%）。大多数患者（98.5%）接受醋硝香豆素治疗，而 1.5%的患者接受华法林治疗，每周治疗剂量分别为 13.6 毫克和 30.4 毫克。对于总诊断，治疗范围内的中位时间为 50%。然而，仅在圣地亚哥省使用远程医疗策略时，观察到更好的结果，即 66.7%。我们的研究结果强调，在智利，每年接受抗凝治疗的患者数量不断增加，远程医疗通过承诺的团队，提高了口服抗凝剂的使用，并能够提高抗凝治疗护理的质量指标。
